Le Lézard
Classified in: Health
Subjects: TDS, FVT

Cardiff Oncology to Present at H.C. Wainwright Global Life Sciences Conference


SAN DIEGO, March 3, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer, castrate-resistant prostate cancer and leukemias, today announced that the Company will present at the upcoming H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021. The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7 a.m. ET on Tuesday, March 9, 2021. The Company will also participate in one-on-one meetings with investors during the conference.

About Cardiff Oncology, Inc.

Cardiff Oncology is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need. Our goal is to overcome resistance, improve response to treatment and increase overall survival.  We are developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Our clinical development programs incorporate tumor genomics and biomarker technology to enable assessment of patient response to treatment. We have three clinical programs that have demonstrated the safety and efficacy of onvansertib: a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin® (bevacizumab) in KRAS-mutated metastatic colorectal cancer (mCRC); a Phase 2 study of onvansertib in combination with Zytiga® (abiraterone)/prednisone in metastatic castration-resistant prostate cancer (mCRPC); and a Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia (AML). A new Phase 2 trial of onvansertib in combination with nanoliposomal irinotecan, leucovorin and fluorouracil for the second-line treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDAC) is planned for initiation in the first half of 2021. For more information, please visit https://www.cardiffoncology.com

Cardiff Oncology Contact:
Vicki Kelemen
Chief Operating Officer
858-952-7652
vkelemen@cardiffoncology.com  

Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com 

Media Contact:
Karen O'Shea, Ph.D.
LifeSci Communications
929-469-3860
koshea@lifescicomms.com 

SOURCE Cardiff Oncology, Inc.


These press releases may also interest you

at 06:30
The Patent and Market Court of Appeal at the Svea Court of Appeal partly confirms the judgment of the Patent and Market Court of 26 July 2019, which gave C-RAD the right to the invention described in the patent application entitled "Ionizing...

at 05:50
ChenMed, a national leader in primary care for underserved seniors, today announced that Atlanta resident James B. "Buck" McCabe has joined its Board of Directors to help the company keep strengthening its culture in a period of sustained hyper...

at 05:15
The "Global Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021" report has been added to ResearchAndMarkets.com's offering. The Global Manufacturing and Supply Partnering Terms and Agreements in...

at 05:10
The "Infectious Disease Diagnostics Market by Product and Solution (Consumables, System, Software and Services), Technology (Immunodiagnostics, PCR, INAAT), Disease (HIV, HAIS, Influenza), End User (Hospital, Reference Lab, Research) - Global...

at 05:00
Based on its recent analysis of the global intrauterine device (IUD) market, Frost & Sullivan recognizes OCON Healthcare (OCON) with the 2021 Global Enabling Technology Leadership Award for creating the world's first and only 3D spherical copper IUD,...

at 05:00
Legal sociologist and human rights activist, Dr. Johan Beckman has added his voice to the many people that have appealed to declare COVID-19 vaccines a global common good so that the vaccines can be produced and distributed for free. "Given that the...



News published on 3 march 2021 at 08:30 and distributed by: